# ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation

Study · id `cardio:ct-nct01184300` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01184300](<https://clinicaltrials.gov/study/NCT01184300>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01184300

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT01184300. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT01184300, source copy `cardio:ctgov-nct01184300-2011-11-11`, retrieved 2026-10-31)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01184300, source copy `cardio:ctgov-nct01184300-2011-11-11`, retrieved 2026-10-31)
- Primary completion: 2011-07 (actual) (ClinicalTrials.gov record NCT01184300, source copy `cardio:ctgov-nct01184300-2011-11-11`, retrieved 2026-10-31)
- Completion: 2011-07 (actual) (ClinicalTrials.gov record NCT01184300, source copy `cardio:ctgov-nct01184300-2011-11-11`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT01184300, source copy `cardio:ctgov-nct01184300-2011-11-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01184300-2011-11-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
- Acronym: RAPID GENE
- Condition: Stable Coronary Artery Disease
- Condition: Acute Coronary Syndrome
- Condition: Percutaneous Coronary Intervention
- Intervention (Genetic): Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19\*2 carriers
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER
- Collaborator: Spartan Bioscience Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)
- Registry lists this organization as a collaborator: Spartan Bioscience Inc. (`cardio:org-spartan-bioscience-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial (`cardio:pubmed-22464343`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c7cd8d24f05eb4d8736da336574cc8ddfc40d3cd2c04b0ebaa083cfa80e511eb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
